Prevalence of potential drug-drug interactions and associated factors among outpatients and inpatients in Ethiopian hospitals: a systematic review and meta-analysis of observational studies.
Drug-drug interactions
Ethiopia
Hospitals
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
24 08 2020
24 08 2020
Historique:
received:
19
12
2019
accepted:
11
08
2020
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
3
7
2021
Statut:
epublish
Résumé
Drug-drug interaction is an emerging threat to public health. Currently, there is an increase in comorbid disease, polypharmacy, and hospitalization in Ethiopia. Thus, the possibility of drug-drug interaction occurrence is high in hospitals. This study aims to summarize the prevalence of potential drug-drug interactions and associated factors in Ethiopian hospitals. A literature search was performed by accessing legitimate databases in PubMed/MEDLINE, Google Scholar, and Research Gate for English-language publications. To fetch further related topics advanced search was also applied in Science Direct and HINARI databases. The search was conducted on August 3 to 25, 2019. All published articles available online until the day of data collection were considered. Outcome measures were analyzed with Open Meta Analyst and CMA version statistical software. Der Simonian and Laird's random effect model, I A total of 14 studies remained eligible for inclusion in systematic review and meta-analysis. From the included studies, around 8717 potential drug-drug interactions were found in 3259 peoples out of 5761 patients. The prevalence of patients with potential drug-drug interactions in Ethiopian hospitals was found to be 72.2% (95% confidence interval: 59.1, 85.3%). Based on severity, the prevalence of major, moderate, and minor potential drug-drug interaction was 25.1, 52.8, 16.9%, respectively, also 1.27% for contraindications. The factors associated with potential drug-drug interactions were related to patient characteristics such as polypharmacy, age, comorbid disease, and hospital stay. There is a high prevalence of potential drug-drug interactions in Ethiopian hospitals. Polypharmacy, age, comorbid disease, and hospital stay were the risk factors associated with potential drug-drug interactions.
Sections du résumé
BACKGROUND
Drug-drug interaction is an emerging threat to public health. Currently, there is an increase in comorbid disease, polypharmacy, and hospitalization in Ethiopia. Thus, the possibility of drug-drug interaction occurrence is high in hospitals. This study aims to summarize the prevalence of potential drug-drug interactions and associated factors in Ethiopian hospitals.
METHODS
A literature search was performed by accessing legitimate databases in PubMed/MEDLINE, Google Scholar, and Research Gate for English-language publications. To fetch further related topics advanced search was also applied in Science Direct and HINARI databases. The search was conducted on August 3 to 25, 2019. All published articles available online until the day of data collection were considered. Outcome measures were analyzed with Open Meta Analyst and CMA version statistical software. Der Simonian and Laird's random effect model, I
RESULTS
A total of 14 studies remained eligible for inclusion in systematic review and meta-analysis. From the included studies, around 8717 potential drug-drug interactions were found in 3259 peoples out of 5761 patients. The prevalence of patients with potential drug-drug interactions in Ethiopian hospitals was found to be 72.2% (95% confidence interval: 59.1, 85.3%). Based on severity, the prevalence of major, moderate, and minor potential drug-drug interaction was 25.1, 52.8, 16.9%, respectively, also 1.27% for contraindications. The factors associated with potential drug-drug interactions were related to patient characteristics such as polypharmacy, age, comorbid disease, and hospital stay.
CONCLUSIONS
There is a high prevalence of potential drug-drug interactions in Ethiopian hospitals. Polypharmacy, age, comorbid disease, and hospital stay were the risk factors associated with potential drug-drug interactions.
Identifiants
pubmed: 32831135
doi: 10.1186/s40360-020-00441-2
pii: 10.1186/s40360-020-00441-2
pmc: PMC7444065
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
BMC Med Inform Decis Mak. 2017 Feb 22;17(1):21
pubmed: 28228132
Biomed Res Int. 2017;2017:9792363
pubmed: 29250554
Drug Metab Dispos. 2003 Jul;31(7):815-32
pubmed: 12814957
Int J Clin Pharmacol Ther. 2000 Nov;38(11):504-13
pubmed: 11097142
J Drug Assess. 2015 Jul 14;4(1):19-23
pubmed: 27536458
Cad Saude Publica. 2014 Sep;30(9):1947-56
pubmed: 25317523
Thromb J. 2014 Sep 17;12:20
pubmed: 25249791
BMC Res Notes. 2016 Sep 01;9(1):431
pubmed: 27585436
Pharmaceutics. 2011 Nov 18;3(4):865-913
pubmed: 24309312
Curr Drug Saf. 2017;12(3):171-177
pubmed: 28625147
BMC Health Serv Res. 2017 Feb 23;17(1):161
pubmed: 28231833
J Clin Diagn Res. 2014 Nov;8(11):HC01-4
pubmed: 25584241
SAGE Open Med. 2019 Jun 11;7:2050312119857353
pubmed: 31217972
Br J Clin Pharmacol. 2009 Aug;68(2):187-93
pubmed: 19694737
Int J Clin Pharm. 2012 Dec;34(6):807-17
pubmed: 22965222
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
World J Gastroenterol. 2016 Jan 21;22(3):1260-78
pubmed: 26811663
Eur J Clin Pharmacol. 2018 Jan;74(1):15-27
pubmed: 29058038
Pharm Pract (Granada). 2013 Oct;11(4):191-5
pubmed: 24367458
Drug Healthc Patient Saf. 2017 Aug 14;9:71-76
pubmed: 28860861
J Bras Nefrol. 2014 Jan-Mar;36(1):26-34
pubmed: 24676611
Asian Pac J Trop Biomed. 2014 May;4(Suppl 1):S204-8
pubmed: 25183081
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Pediatrics. 2007 Jan;119(1):e77-85
pubmed: 17200262
BMC Med Inform Decis Mak. 2015 Aug 28;15:74
pubmed: 26315024
J Pharmacol Pharmacother. 2012 Oct;3(4):304-7
pubmed: 23326100
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Drug Saf. 2008;31(6):525-36
pubmed: 18484786
Resuscitation. 2001 Jun;49(3):283-8
pubmed: 11719123
Biopharm Drug Dispos. 2015 Mar;36(2):71-92
pubmed: 25545151
J Adv Pharm Technol Res. 2013 Oct;4(4):183-9
pubmed: 24350048
Eur J Clin Pharmacol. 2012 Dec;68(12):1667-76
pubmed: 22644345
Daru. 2014 Jun 25;22:52
pubmed: 24965959
J Crit Care. 2018 Feb;43:1-6
pubmed: 28822348